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OBJECTIVE — To estimate prevalence of, and factors associated with, sustained periods of
hyperglycemia among patients with diabetes and factors associated with receipt of appropriate
care once A1C values are persistently elevated.
RESEARCH DESIGN AND METHODS — Among patients initiating oral monotherapy
(n5,070),Kaplan-MeierandCoxproportionalhazardsmethodswereusedtoestimatetimeto,
and factors associated with, sustained hyperglycemia (deﬁned by two A1cs 8% and no recent
medication intensiﬁcation), and among those experiencing sustained hyperglycemia, time to,
andfactorsassociatedwith,appropriatereceiptofcare(i.e.,medicationintensiﬁcationorachiev-
ing A1C 7%).
RESULTS — Within 1 year, 8% experienced sustained hyperglycemia, with the proportion
rising to 38% within 5 years. Patients using sulfonylurea had greater risk of hyperglycemia
(hazard ratio [HR] 1.47 [95% CI 1.30–1.66]) compared with those initiating metformin. Risk
increased with age (1.89 [1.27–2.83]), was greater for African Americans (1.19 [1.05–1.36]),
and increased with A1C levels 7%. Among individuals with sustained hyperglycemia (n 
1,386), mean time to appropriate care was 9.7 months, with 25% not receiving appropriate care
within 1 year. Shorter delays to appropriate care receipt were associated with increasing income
(1.03 [1.00–1.07]), A1C 9% (1.38 [1.06–1.79]) and 11% (1.65 [1.25–2.18]), increasing
medication adherence (1.03 [1.01–1.04]), and visits to primary care (4.22 [3.65–4.88]) or
endocrinology (3.89 [2.26–6.70]). Longer delays were associated with increasing drug copay-
ments (0.96 [0.93–0.98]).
CONCLUSIONS — Patients incurring sustained hyperglycemia are at risk of further delays
in appropriate management. Barriers to appropriate care include prescription drug copayments,
few physician contacts, and other factors that are likely amenable to intervention.
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C
linical inertia among patients with
diabetes reﬂects the proportion of
patients with elevated glycosylated
hemoglobin (A1C) and no intensiﬁcation
of pharmacological therapy. Prior re-
search has found that between 33 and
66% of patients with an elevated A1C do
not have timely intensiﬁcation of their
medications(1–7).Numerousclinicaltri-
als have provided consistent evidence of
the detriment of prolonged periods of hy-
perglycemia among adults with type 2 di-
abetes (8,9), and few would argue that
once A1C values are substantially and
consistently above target levels, intensiﬁ-
cation of pharmacological therapy is
warranted.
Although the presence of poor con-
trolindiabeteshasbeendocumented,the
extent to which patients with diabetes in-
cur sustained periods of poor control and
norecentmedicationintensiﬁcationisnot
well quantiﬁed. Nor is it known what fac-
tors eventually facilitate the receipt of ap-
propriate care once a patient incurs a
sustained period of poor control. Among
a cohort of patients initiating oral mono-
therapy, we report the risk of, and factors
associated with, sustained hyperglycemia
and evaluate factors associated with re-
ceipt of appropriate care among individ-
uals with sustained hyperglycemia.
RESEARCH DESIGN AND
METHODS
Setting and population
Study-eligible patients received care from
a multispecialty group practice in south-
east Michigan and were aged 18 years or
older when initiating oral monotherapy
between 2000 and 2005. Therapy initia-
tion was deﬁned as a dispensing for an
oral antidiabetic agent preceded by 6
months in which no antidiabetic agent
was dispensed. Eligible patients had con-
tinuous health plan enrollment during
the 6-month period immediately before
and after therapy initiation and had two
or more A1C tests during follow-up.
Data sources
Automated administrative records were
used to compile demographic informa-
tion (i.e., age, sex, race, and marital sta-
tus), dates and type of health plan
enrollment (i.e., employer sponsored
versus Medicare risk versus Medicare
supplemental), a linear measure of
prescription drug copayment, and resi-
dentialstreetaddress.Thelatterwascom-
bined with data from the 2000 U.S.
Census to construct estimates of median
householdincomeinthepatient’scensus-
block of residence (10). Medical claims
data were used to capture information on
ambulatory care visits, inpatient hospital
admissions, and associated diagnostic
codes (i.e., ICD-9-CM codes). Inpatient
and outpatient diagnostic information
wasusedtoconstructmeasuresofcomor-
bidities and complications associated
with diabetes (i.e., amputation, carotid
endarterectomy, end-stage renal disease,
heart failure, hypertension, left ventricu-
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tient discharge diagnoses and procedure
codes were used to construct indicators
reﬂective of cardiac events (i.e., angina,
angiogram, bypass, myocardial infarc-
tion, peripheral vascular disease, stroke,
and transient ischemic attack). Dates and
results of all A1C testing were compiled
from a clinical information system.
Pharmacy claims data were used to
constructdichotomousﬂagsofantidiabetic,
antihypertensive,cholesterol-lowering,and
antidepression medication use. We used
days supply information from dispensing
data to measure medication adherence
(with a medication possession ratio) in the
periods immediately after oral mono-
therapy initiation and immediately preced-
ing the date of sustained hyperglycemia
(11). Among the subgroup of patients with
sustained hyperglycemia, we also used the
latest dispensing information available be-
tween inception date and the date of the
patient’s second elevated A1C to determine
whether the patient was still receiving
monotherapy or had changed to combina-
tion oral therapy. For each of these mea-
sures, medications paid for by the health
planwereknown,regardlessofthedispens-
ing pharmacy.
Study outcomes
Sustained hyperglycemia was deﬁned
when a second A1C test result 8% was
recorded with at least 90 days between
that result and the prior elevated result,
with no intermediate test result 7% and
no medication change in the 90 days pre-
ceding the second test. Among individu-
als facing sustained hyperglycemia, we
constructed a measure reﬂecting time (in
days)fromthedateofsustainedhypergly-
cemia (i.e., second elevated A1C) to the
ﬁrstdatethepatienthadapharmaceutical
dispensing indicating therapy intensiﬁca-
tion (i.e., time to therapy intensiﬁcation).
Therapy intensiﬁcation included the ad-
dition of an oral agent, an increase in oral
agent dose, a change in oral agent class,
the addition of insulin, or any combina-
tion of these. We also constructed a mea-
sure reﬂecting time (in days) from the
dateofsustainedhyperglycemiatothere-
ceipt of “appropriate care.” Appropriate
care was deﬁned as either a pharmaceuti-
cal dispensing of a therapy intensiﬁcation
or an A1C test result 7% (6).
Statistical analysis
We used Kaplan-Meier methods to esti-
mate mean time to sustained hyperglyce-
mia and proportion facing sustained
hyperglycemia annually from inception
(i.e., initiation of oral monotherapy). We
ﬁt a Cox proportional hazards model to
evaluate patient factors associated with
sustained hyperglycemia. Prescription
drug copayment, diabetic complications,
and cardiac events were evaluated as
time-varying covariates with diabetic
complications and cardiac events treated
as ﬂags that turned on (and stayed on) as
of the date of ﬁrst occurrence. Patients
were followed from therapy initiation
through the ﬁrst of health plan disenroll-
ment, insulin initiation, or 31 December
2005. (Patients were censored at insulin
initiation because of inherent challenges
with using claims data alone to monitor
changes in insulin dosing.)
Among the subset of eligible patients
experiencing sustained hyperglycemia
and no recent medication intensiﬁcation
during follow-up, we used Kaplan-Meier
methods to describe time to medication
intensiﬁcation and appropriate care. For
these estimates, patients were followed
from the date of their second elevated
A1C through the ﬁrst of health plan dis-
enrollment or medication intensiﬁcation/
appropriate care. Cox proportional
hazards models were used to evaluate the
factorsassociatedwithtimetomedication
intensiﬁcation and appropriate care.
Table 1—Characteristics of the oral monotherapy and sustained hyperglycemia cohorts at
time of oral monotherapy initiation
Oral
(monotherapy cohort)
Sustained
(hyperglycemia cohort)
n 5,070 1,358
Sociodemographic characteristics
Age (years) 60  13 58  12
Female (%) 48 45
Race (%)
White 57 50
African American 37 45
Other 5 5
Marital status (%)
Married 67 65
Not married/unknown 33 35
Insurance type (%)
Employer-sponsored 60 67
Medicare risk 23 21
Medicare complimentary 17 13
Prescription drug copayment (USD) $5.00 (0, 35) $3.00 (0, 35)
Household income (USD)* $49,631  22,133 $47,569  20,890
Hyperglycemia medication therapy (%)
Sulfonylurea 52 59
Metformin 45 38
Other monotherapy 4 3
Adherence (%) 83.1  25.1 82.2  24.9
Glycemic control (%)
A1C level† 8.6  2.2 9.6  2.3
By category
A1C 7% 19 6
7  A1C 8% 19 12
8  A1C 9% 13 16
9  A1C 11% 13 21
A1C 11% 11 18
Untested (%) 26 28
Length of observation
Months‡ 44.5  17.2 52.7  13.8
Data are means  SD and median (min, max) unless otherwise indicated. *Geo-coded median household
income by residential zip code. †A1C level is deﬁned by the most recent value available in the preceding 3
monthsorsubsequent1month.‡Timeinmonthsfromoralmonotherapyinitiationtoﬁrstofdisenrollment,
insulin initiation, or 31 December 2005.
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istics(age,race,sex,maritalstatus,typeof
insurance coverage, household income)
and lipid lowering, antihypertensive, and
antidepressant medication use were eval-
uated at the time of sustained hyperglyce-
mia. Antidiabetic medication use (i.e.,
oral mono- or combination therapy) was
also assessed at the time of sustained hy-
perglycemia, as was the patient’s recent
6-month adherence to this therapy. Pre-
scription drug copayment, A1C level, di-
abetic complications, cardiac events,
inpatient admissions, and visits to pri-
mary care, endocrinology, cardiology,
andtheemergencydepartmentwereeval-
uated as time-varying covariates. Diabetic
complications and cardiac events were
treated as ﬂags that turned on (and stayed
on) as of date of ﬁrst occurrence, whereas
inpatient admission, emergency depart-
ment visit, and ofﬁce visit events were
ﬂagged on the date of each occurrence
and remained ﬂagged until 30 days after
the date of the event.
All Cox proportional hazards models
were ﬁt with the robust variance estima-
tionmethodinPROCPHREGinSAS(12)
to account for the potential nonindepen-
dence of observations (i.e., patients)
treated by the same physician. All models
controlled for the year the patient initi-
ated oral monotherapy and, in the case of
appropriate care/intensiﬁcation, the
length of time between the two A1C tests
deﬁning the period of sustained
hyperglycemia.
RESULTS
Cohort characteristics
Table1describesthecohortinitiatingoral
monotherapy (n  5,070) and the subset
of this cohort who incurred a sustained
period of hyperglycemia during fol-
low-up (n  1,386). The average age of
the cohort was just over 60 years. A total
of48%werefemaleand37%wereAfrican
American, whereas approximately two-
thirds were married. The majority had
their health plan coverage via an employ-
er-sponsored plan, and the median pre-
scription drug copayment faced was
$5.00. Per the cohort inclusion criteria,
all were dispensed oral monotherapy
(most often a sulfonylurea or metformin)
at baseline. Mean adherence in the
6-month period after dispensing was
83.1  25.1% (means  SD). At the time
patients were dispensed the oral agent,
74% had an A1C measurement on record
in the preceding 3 months or following 1
month. Among individuals with an A1C
on record, mean A1C was 8.6  2.3%.
Patients were observed for an average of
almost 4 years (45 months, range 6–73).
Prevalence of and factors associated
with sustained hyperglycemia
Among the cohort, 1,386 patients were
observedtohaveaperiodofsustainedhy-
perglycemiaandnorecentmedicationin-
tensiﬁcation during follow-up. Just over
one-third of individuals had been dis-
pensed oral combination therapy before
incurring sustained hyperglycemia. The
mean adherence to antidiabetic medica-
tions in the 3-month period preceding
sustained hyperglycemia was 64.4 
42.2%. Furthermore, at the time of sus-
tained hyperglycemia, the mean A1C of
the cohort was 9.7  1.7%, with 38%
incurringanA1Cbetween9and11%and
20%incurringanA1C11%.Amongin-
Table 2—Factors associated with a sustained period of hyperglycemia among patients initi-
ating oral monotherapy: Cox proportional hazards regression results (n  4,912)*
Hazard ratio (95% CI) P
Sociodemographic characteristics
Age in decades 1.89 (1.27–2.83) 0.01
Male 1.11 (0.99–1.24) 0.08
Race
White 1.00
African American 1.19 (1.05–1.36) 0.01
Other 1.17 (0.91–1.50) 0.23
Married 0.84 (0.75–0.95) 0.01
Insurance type
Employer-sponsored 1.00
Medicare risk 1.39 (1.13–1.71) 0.01
Medicare complimentary 0.98 (0.78–1.23) 0.88
Income (in 10K USD increments) 0.97 (0.94–1.00) 0.05
Prescription drug copayment (USD) 0.94 (0.90–0.97) 0.01
Medication use
Hyperglycemia medication regimen
Metformin 1.00
Sulfonylurea 1.47 (1.30–1.66) 0.01
Other monotherapy 1.04 (0.74–1.46) 0.82
Hyperglycemia medication
adherence (in 10% increments) 0.98 (0.96–1.00) 0.04
Other current medications
Antihypertensive agent 1.08 (0.95–1.23) 0.24
Cholesterol-lowering agent 1.20 (1.04–1.39) 0.01
Antidepressive agent 1.11 (0.94–1.32) 0.22
Comorbidities and complications
Amputation 0.83 (0.27–2.58) 0.75
Cardiovascular event 0.99 (0.96–1.01) 0.23
Carotid endarterectomy 1.86 (0.66–5.19) 0.24
End-stage renal disease 0.55 (0.38–0.79) 0.01
Heart failure 1.12 (0.77–1.64) 0.55
Hypertension 0.92 (0.80–1.06) 0.26
Left ventricular hypertrophy 0.49 (0.20–1.17) 0.11
Retinopathy 1.07 (0.87–1.32) 0.50
Glycemic control
No test at therapy initiation 3.20 (2.53–4.06) 0.01
A1C level
7% 1.00
7–7.9% 2.44 (1.88–3.16) 0.01
8–8.9% 4.58 (3.55–5.91) 0.01
9–10.9% 5.97 (4.65–7.66) 0.01
11% 5.94 (4.60–7.66) 0.01
*A total of 153 patients did not have income and 5 did not have copay data available.
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the mean length of observation from that
date forward was 22 months (range
1–69).
Results from the Kaplan-Meier esti-
mates of time from initiation of an-
tidiabetic monotherapy to sustained
hyperglycemia indicate that 8% of pa-
tients incurred sustained hyperglycemia
within 12 months and that this propor-
tionsteadilyroseovertime,with38%fac-
ing a period of sustained hyperglycemia
within 5 years. The mean length of time
between the two elevated A1C values
used to deﬁne the sustained period (that
is, the mean length of time the patient
incurred hyperglycemia when labeled
“sustained”)was7.69.7months(range
3–64). Of note among the Cox propor-
tional hazards model ﬁndings (Table 2)
was that the risk of incurring sustained
hyperglycemia increased with increasing
age and A1C levels 7%. Risk was also
greater for African American patients and
those who originally initiated a sulfonyl-
urea (compared with those initiating
metformin).Ontheotherhand,riskde-
creased with increasing income and
medication adherence.
Time to appropriate care
Onceapatientwithdiabetesincurredsus-
tained hyperglycemia, the median time to
appropriatecarewasanother3.9months.
As illustrated in Fig. 1, whereas 59% of
patients received appropriate care within
6 months, by the end of 12 months, 25%
of patients had not received appropriate
care, and at the end of 2 years, 11% still
had not received appropriate care. If re-
turntoglycemiccontrolisnotconsidered
(i.e., a medication intensiﬁcation only),
median time increases to 4.1 months and
the proportion continuing to have an ele-
vated A1C without an intensiﬁcation is
42% at 6 months, 27% at 12 months, and
14% at 2 years. Of note is the fact that,
without intensiﬁcation, 5% of patients
returntoglycemiccontrolwhencontrolis
deﬁnedby7%,andonlyanadditional4%
return to control without intensiﬁcation
when control is deﬁned by 8%.
Factors associated with appropriate
care receipt after sustained
hyperglycemia
Time to appropriate care signiﬁcantly de-
creases as income increases (Table 3).
Furthermore, appropriate care receipt is
facilitated by patient medication adher-
ence,recenthospitaladmission,andvisits
to primary care and endocrinology. Pa-
tients with an A1C value between 9 and
11%,aswellasthosewithanA1C11%,
also have reduced delays in the receipt of
appropriate care compared with individ-
uals with A1C values between 8 and 9%.
Delays are longer for those dispensed
combination therapy and increase with
increasingprescriptiondrugcopayments.
Model ﬁndings and results do not differ
substantivelywhentimetomedicationin-
tensiﬁcation only is considered (data not
shown).
CONCLUSIONS — Control of hy-
perglycemia has long been identiﬁed as a
challenge in the care of patients with dia-
betes.Amongpatientsinitiatingoralther-
apy, we found periods of hyperglycemia
exceeding 3 months (and averaging al-
most 10 months) to be commonplace:
25% of patients incurred a sustained pe-
riod of hyperglycemia within 3 years of
initiating oral monotherapy. The risk of
sustained hyperglycemia and no recent
medication intensiﬁcation was notably
greater for African American patients as
well as those dispensed a sulfonylurea
and increased with increasing age and
A1Clevels.Ontheotherhand,increasing
income and medication adherence were
protective of sustained hyperglycemia.
Speciﬁc reasons behind some of these
ﬁndings can only be speculated. For ex-
ample, whereas it may be that clinicians
are less aggressive in treating older and
African American patients, it may be that
older and African American patients pre-
ferlessaggressivetreatmentorsomecom-
bination of these factors.
Furthermore, we found that 41% of
patientsexperiencingsustainedhypergly-
cemia did not receive appropriate care (as
evidenced by an intensiﬁcation of treat-
Figure 1—Time to medication intensiﬁcation (pharmaceutical dispensing indicating addition of oral agent, increase in oral agent dose, change in
oral agent class, addition of insulin, or any combination of these) and appropriate care (medication intensiﬁcation or A1C test result 7%) (n 
1,386) among individuals with sustained hyperglycemia.
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months of their second elevated A1C. A
quarter of the patients did not receive ap-
propriatecare12monthslater,andonein
nine still had no evidence of appropriate
care 2 years later. Such ﬁndings are trou-
bling because multiple clinical trials have
provided evidence of the detriment of
sustained hyperglycemia among adults
with type 2 diabetes (8,9).
We found delays in appropriate care
decreased as the per capita income in the
patient’s community of residence in-
creased and as the patient’s prescription
drug copayment decreased. These ﬁndings
translate into substantive differences in the
length of delays. For example, patients re-
siding in communities with median house-
holdincomesof$20,000haveahazardrate
22% less favorable than that for patients
who reside in communities with median
household incomes of $80,000. Further-
more, the Kaplan-Meier estimated median
length of delay in appropriate care for pa-
tients facing a $5.00 prescription drug co-
paymentwasjustunder4months,whereas
the median delay for those facing a $7.00
copayment was just over 6.5 months.
Taken together, these ﬁndings call into
question the merits of across-the-board in-
creases in patient ﬁnancial burdens. In-
stead, they support the recent movement
among some employers toward “value-
based insurance design” (13). Under such
plans, copayments for some medications
(includingthoseusedtotreatdiabetescare)
are reduced explicitly to encourage appro-
priate use (14).
Wealsofoundthatthelikelihoodofap-
propriate care increases substantially with a
recent ambulatory care visit—regardless of
whether the visit is to a primary care physi-
cian or an endocrinologist. Other studies
have yielded similar results (6,15). While
inpatient admissions also serve to shorten
the time to appropriate care, one could
speculate that at least some of these admis-
sions might have been avoided if intensiﬁ-
cation occurred sooner.
Furthermore, we found that patients
already dispensed combination oral ther-
apy before incurring sustained hypergly-
cemia have an 18% less favorable hazard
ratio for receipt of appropriate care than
patients who remained on monotherapy.
Whereas we cannot speciﬁcally link this
ﬁnding to insulin initiation, it is consis-
tent with the hypothesis that physicians
andpatientshavepsychologicalandother
barriers to initiating insulin therapy
(16–21).
As others have also observed, delays in
appropriatecareappearcommonplaceuntil
A1C levels reach 9% (3,6,15,22,23). We
cannot discern whether such inactivity be-
low9%isattributabletoafailuretorealizea
likely need for therapy intensiﬁcation, pa-
tient preferences, physician preferences, or
acombinationoftheseandotherfactors.Of
note, however, is the fact that 5% of pa-
tients return to glycemic control without
intensiﬁcation.
Finally,wefounddelaysinthereceipt
of appropriate care among those less ad-
herent to hyperglycemia medications. Al-
though not frequently studied, this
ﬁnding is consistent with that of Grant et
al. (4). Whereas intensiﬁcation of therapy
Table 3—Factors associated with appropriate care receipt among patients with sustained
hyperglycemia: Cox proportional hazards regression results (n  1,358)*
Hazard ratio (95% CI) P
Sociodemographic characteristics
Age in decades 0.94 (0.86–1.03) 0.19
Male 0.97 (0.85–1.11) 0.67
Race
White 1.00
African American 0.88 (0.76–1.02) 0.08
Other 0.90 (0.68–1.19) 0.47
Married 0.94 (0.82–1.08) 0.36
Insurance type
Employer-sponsored 1.00
Medicare risk 0.97 (0.77–1.23) 0.81
Medicare complimentary 0.99 (0.78–1.27) 0.96
Income (in 10K USD increments) 1.03 (1.00–1.07) 0.05
Prescription drug copayment (USD) 0.96 (0.93–0.98) 0.01
Medication use
Hyperglycemia medication regimen
Oral monotherapy 1.00
Oral combination therapy 0.82 (0.71–0.94) 0.01
Hyperglycemia medication
adherence (in 10% increments) 1.03 (1.01–1.04) 0.01
Other current medications
Antihypertensive agent 1.26 (1.09–1.47) 0.01
Cholesterol-lowering agent 1.26 (1.08–1.46) 0.01
Antidepressive agent 1.49 (1.19–1.87) 0.01
Medical care visit event(s)
Inpatient admission 1.68 (1.02–2.75) 0.04
Emergency department 1.19 (0.80–1.76) 0.40
Primary care 4.22 (3.65–4.88) 0.01
Endocrinology 3.89 (2.26–6.70) 0.01
Cardiology 0.99 (0.70–1.41) 0.97
Comorbidities and complications
Amputation 0.62 (0.21–1.77) 0.37
Cardiovascular event 1.01 (0.81–1.25) 0.93
Carotid endarterectomy 1.40 (0.49–4.04) 0.53
End-stage renal disease 1.16 (0.84–1.59) 0.38
Heart failure 0.98 (0.67–1.44) 0.93
Hypertension 0.85 (0.71–1.02) 0.08
Left ventricular hypertrophy 1.73 (0.82–3.65) 0.15
Retinopathy 0.96 (0.79–1.18) 0.71
Glycemic control
A1C level
8% 1.00
8–9% 0.94 (0.73–1.22) 0.64
9–11% 1.38 (1.06–1.79) 0.02
11% 1.65 (1.25–2.18) 0.01
*A total of 28 patients did not have income data available.
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scribed medications is rarely clinically in-
dicated, there is growing evidence that
physicians are often unaware of their pa-
tient’s medication adherence status (24).
Our study is not without limitations.
The use of pharmaceutical claims data to
evaluate medication intensiﬁcations means
that prescriptions provided to patients but
never ﬁlled are not identiﬁed (as are those
ﬁlled but paid for by another source) and
assumes that medications dispensed were
ingested. Likewise, because A1C testing is
often supplemented with home glucose
monitoring, the clinical control measure
may be different from that known by pa-
tients and providers in practice. Further-
more, some patients may have clinical
conditionsthatmakemedicationchangein-
appropriate.Yet,wefocusonthosepatients
with two elevated A1C test results—or
those for whom an intensiﬁcation is likely
mostwarranted—andareabletocontrolfor
medicationadherencewhenevaluatingfac-
tors associated with receipt of appropriate
care. Furthermore, the small sample size
may have contributed to some of the non-
statistically signiﬁcant ﬁndings (partic-
ularly that of race and age) in the time-to-
appropriate-care equation. Finally, care
shouldbetakenwhengeneralizingﬁndings
to other populations, especially those that
are uninsured.
Our study is one of few to quantify de-
lays in appropriate care receipt among pa-
tients with diabetes and one of the ﬁrst to
evaluate simultaneously patient, physician,
and system factors associated with appro-
priate care receipt. Findings highlight that
no one person or thing is to blame when
care quality falls short. Instead, receipt of
quality care results from a complex system
offactors.Althoughthedecisiontointensify
diabetes medication is one usually associ-
ated with physicians, to be effective, inter-
ventions targeting improvements in
pharmacological management should con-
sider a broad array of factors. These include
the ﬁnancial barriers patients may face, the
importance of access to routine visits, and
possible psychological barriers to appropri-
ate care. The good news is that many of
these factors appear amenable to clinical
and public policy changes.
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